NCT06495476View on ClinicalTrials.gov

Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

144

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Mild Cognitive Impairment

Interventions

DRUG

Ginkgo biloba extract 50 dropping pills

Composition: Ginkgo ketone ester, excipient polyethylene glycol 6000. Size: 10mg ginkgolides/pill.

DRUG

Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant

"Composition: The main ingredient is polyethylene glycol 6000 + caramel pigment, placebo and ginkgolide drops are basically the same in color, odor and appearance.~Size: 10 mg analog ingredient/pill."

All Listed Sponsors

lead

Beijing Tiantan Hospital

OTHER

NCT06495476 - Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD | Biotech Hunter | Biotech Hunter